Nanjing Key Lab of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China.
Am J Physiol Renal Physiol. 2021 Apr 1;320(4):F608-F616. doi: 10.1152/ajprenal.00554.2020. Epub 2021 Feb 22.
Stimulator of interferon genes (STING) is an important adaptor in cytosolic DNA-sensing pathways. A recent study found that the deletion of STING ameliorated cisplatin-induced acute kidney injury (AKI), suggesting that STING could serve as a potential target for AKI therapy. Up to now, a series of small-molecule STING inhibitors/antagonists have been identified. However, none of the research was performed to explore the role of human STING inhibitors in AKI. Here, we investigated the effect of a newly generated covalent antagonist, H151, which targets both human and murine STING, in cisplatin-induced AKI. We found that H151 treatment significantly ameliorated cisplatin-induced kidney injury as shown by the improvement of renal function, kidney morphology, and renal inflammation. In addition, tubular cell apoptosis and increased renal tubular injury marker neutrophil gelatinase-associated lipocalin induced by cisplatin were also effectively attenuated in H151-treated mice. Moreover, the mitochondrial injury caused by cisplatin was also reversed as evidenced by improved mitochondrial morphology, restored mitochondrial DNA content, and reversed mitochondrial gene expression. Finally, we observed enhanced mitochondrial DNA levels in the plasma of patients receiving platinum-based chemotherapy compared with healthy controls, which could potentially activate STING signaling. Taken together, these findings suggested that H151 could be a potential therapeutic agent for treating AKI possibly through inhibiting STING-mediated inflammation and mitochondrial injury. Although various stimulator of interferon genes (STING) inhibitors have been identified, no research was performed to investigate the role of human STING inhibitors in AKI. Here, we evaluated the effect of H151 targeting both human and murine STING on cisplatin-induced AKI and observed a protection against renal injury possibly through ameliorating inflammation and mitochondrial dysfunction.
干扰素基因刺激物(STING)是细胞质 DNA 感应途径中的重要衔接蛋白。最近的一项研究发现,STING 的缺失可改善顺铂诱导的急性肾损伤(AKI),提示 STING 可作为 AKI 治疗的潜在靶点。迄今为止,已经鉴定出一系列小分子 STING 抑制剂/拮抗剂。然而,目前尚无研究探索人类 STING 抑制剂在 AKI 中的作用。在这里,我们研究了一种新生成的靶向人类和鼠类 STING 的共价拮抗剂 H151 在顺铂诱导的 AKI 中的作用。我们发现 H151 治疗可显著改善顺铂诱导的肾损伤,表现为肾功能、肾脏形态和肾脏炎症的改善。此外,H151 处理还可有效减轻顺铂诱导的肾小管细胞凋亡和增加肾小管损伤标志物中性粒细胞明胶酶相关脂质运载蛋白。此外,顺铂引起的线粒体损伤也得到逆转,表现为线粒体形态改善、线粒体 DNA 含量恢复和线粒体基因表达逆转。最后,我们观察到接受铂类化疗的患者血浆中线粒体 DNA 水平升高,与健康对照组相比,这可能潜在地激活 STING 信号。综上所述,这些发现表明 H151 可能通过抑制 STING 介导的炎症和线粒体损伤成为治疗 AKI 的潜在治疗剂。尽管已经鉴定出多种干扰素基因刺激物(STING)抑制剂,但目前尚无研究调查人类 STING 抑制剂在 AKI 中的作用。在这里,我们评估了靶向人类和鼠类 STING 的 H151 对顺铂诱导的 AKI 的影响,观察到对肾脏损伤的保护作用,可能是通过改善炎症和线粒体功能障碍。